ATE269089T1 - Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen - Google Patents

Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen

Info

Publication number
ATE269089T1
ATE269089T1 AT98957308T AT98957308T ATE269089T1 AT E269089 T1 ATE269089 T1 AT E269089T1 AT 98957308 T AT98957308 T AT 98957308T AT 98957308 T AT98957308 T AT 98957308T AT E269089 T1 ATE269089 T1 AT E269089T1
Authority
AT
Austria
Prior art keywords
vitamin
derivatives
increase
effect
cytotoxic
Prior art date
Application number
AT98957308T
Other languages
English (en)
Inventor
Candace Johnson
Donald Trump
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of ATE269089T1 publication Critical patent/ATE269089T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98957308T 1997-08-29 1998-08-27 Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen ATE269089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/921,170 US6087350A (en) 1997-08-29 1997-08-29 Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
PCT/US1998/017732 WO1999016451A1 (en) 1997-08-29 1998-08-27 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents

Publications (1)

Publication Number Publication Date
ATE269089T1 true ATE269089T1 (de) 2004-07-15

Family

ID=25445023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957308T ATE269089T1 (de) 1997-08-29 1998-08-27 Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen

Country Status (10)

Country Link
US (5) US6087350A (de)
EP (2) EP1491198A1 (de)
JP (1) JP2001517705A (de)
AT (1) ATE269089T1 (de)
AU (1) AU1359499A (de)
DE (1) DE69824622T2 (de)
DK (1) DK1030670T3 (de)
ES (1) ES2222615T3 (de)
PT (1) PT1030670E (de)
WO (1) WO1999016451A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) * 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
EP1276482B1 (de) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Kombinationschemotherapie
WO2001091794A2 (en) 2000-05-30 2001-12-06 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU7895601A (en) * 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
CN1441674A (zh) * 2000-09-18 2003-09-10 福荷福尔丁和考有限公司 二磷酸盐溶液
AU2001291239A1 (en) * 2000-10-06 2002-04-22 Abbott Laboratories Use of vitamin d2 compounds for alopecia
US20070043110A1 (en) * 2001-06-01 2007-02-22 Summa Health System Nontoxic potentiation sensitization of ovarian cancer therapy by supplementary treatment with vitamins
US7091241B2 (en) * 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
MXPA04001731A (es) * 2002-06-24 2004-05-31 King Pharmaceuticals Res & Dev Tratamiento mejorado de cancer resistente a multiples farmacos con antagonistas de adenosina a3.
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
EP1734972A4 (de) * 2004-03-29 2007-08-22 Roswell Park Cancer Inst Verfahren zur behandlung von soliden tumoren und leukämien unter verwendung einer kombinationstherapie aus vitamin d und antistoffwechsel-nukleosid-analogen
WO2005097128A1 (en) * 2004-03-30 2005-10-20 Novacea, Inc. 1,4-bis-n-oxide azaanthracenediones and the use thereof
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20100255117A1 (en) * 2007-04-06 2010-10-07 The Johns Hopkins University Methods and compositions for the treatment of cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2211615A4 (de) * 2007-10-22 2010-10-13 Glaxosmithkline Llc Pyridosulfonamidderivate als pi3-kinase-hemmer
CA2981549A1 (en) * 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
US9061040B2 (en) 2011-08-15 2015-06-23 Mihai Ciustea Combination therapy for breast cancer
WO2017136671A1 (en) * 2016-02-04 2017-08-10 Chattterjee Bandana Combination therapy for castration-resistant prostate cancer
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
ES3004959T3 (en) 2019-11-08 2025-03-13 Ericsson Telefon Ab L M Determining phase tracking reference signals in multiple transmission points

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3741996A (en) * 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US4670190A (en) * 1973-01-10 1987-06-02 Hesse Robert H 1-α-hydroxy vitamin D compounds and process for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4160803A (en) * 1978-03-23 1979-07-10 Corning Glass Works Self packaged test kit
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4508651A (en) * 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5321016A (en) * 1986-10-30 1994-06-14 Sandoz Pharmaceuticals Corp. Use of certain substituted α-amino acids in treating stress-related psychiatric disorders
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
EP0296800B1 (de) * 1987-06-23 1991-10-16 Yamanouchi Pharmaceutical Co. Ltd. Vitamin D3-Derivate
US4902481A (en) * 1987-12-11 1990-02-20 Millipore Corporation Multi-well filtration test apparatus
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4804502A (en) 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US5087619A (en) * 1988-01-20 1992-02-11 Hoffman-La Roche Inc. Vitamin D3 analogs
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5321018A (en) * 1989-03-09 1994-06-14 Wisconsin Alumni Research Foundation Use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
US5219528A (en) * 1989-07-28 1993-06-15 Pierce Chemical Company Apparatus for rapid immunoassays
DE4011682A1 (de) * 1990-04-06 1991-10-10 Schering Ag 24-oxa-derivate in der vitamin d-reihe
US5194248A (en) * 1990-06-21 1993-03-16 Trustees Of Boston University Compositions comprising vitamin D analog precursors and the use thereof
EP0503035B1 (de) * 1990-09-21 2001-12-12 Bone Care International, Inc. Neues 1alpha-hydroxy vitamin-d4 und neue zwischenprodukte und analoge
US6025346A (en) * 1990-09-21 2000-02-15 Bone Care International, Inc. 1α-hydroxy vitamin D4 and novel intermediates and analogues
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5789397A (en) * 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
AU1247592A (en) * 1991-01-08 1992-08-17 Lunar Corporation Methods for preparation and use of 1alpha,24-dihydroxy vitamin d2
DE4101953A1 (de) * 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
US5417923A (en) * 1991-04-24 1995-05-23 Pfizer Inc. Assay tray assembly
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
CZ280874B6 (cs) * 1991-06-28 1996-04-17 University Of Miami Přípravek pro prevenci nebo redukci chemoterapií indukované alopecie
US5486509A (en) 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
ATE143007T1 (de) * 1991-07-05 1996-10-15 Duphar Int Res Vitamin-d derivat, verfahren zu dessen herstellung sowie zwischenprodukte dafür
US5205989A (en) * 1991-09-18 1993-04-27 Minnesota Mining And Manufacturing Company Multi-well filtration apparatus
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
CA2148109C (en) * 1993-09-01 1999-11-23 Yuji Makino 1.alpha., 24-(oh)2-v.d.3 emulsion composition
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6040300A (en) * 1995-04-07 2000-03-21 Arch Development Corporation Method of preventing colon cancer with vitamin D3 analogues
US5616571A (en) 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
DE69606680T2 (de) * 1995-10-30 2000-08-17 F. Hoffmann-La Roche Ag, Basel 1-Alpha, 26-dihydroxy-D-homo-vitamin D3
DE19644049A1 (de) * 1995-11-11 1997-05-28 Basf Magnetics Gmbh Verfahren und Vorrichtung zum Demontieren von Bandkassetten
US6162801A (en) 1995-11-20 2000-12-19 Kita; Kiyoshi External ophthalmic preparation containing vitamin D
AU1152997A (en) * 1995-12-28 1997-07-28 Chugai Seiyaku Kabushiki Kaisha Malignant tumor metastasis inhibitors
US6869940B2 (en) * 1995-12-28 2005-03-22 Chugai Seiyaku Kabushiki Kaisha Malignant tumor metastasis inhibitors
AU710931B2 (en) * 1996-02-28 1999-09-30 Sumitomo Pharmaceuticals Company, Limited Crystalline vitamin D derivative
DE19619036A1 (de) * 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5939456A (en) 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US5902906A (en) * 1997-05-01 1999-05-11 Albemarle Corporation Alkanethiolation process
US6187764B1 (en) * 1997-05-05 2001-02-13 Angelina Pinal Buttz A and D vitamins and their metabolites: A new treatment for seasonal allergic rhinitis and atopy
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
JP2002510304A (ja) 1997-06-06 2002-04-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 移植体拒絶反応を防ぐためのビタミンｄ化合物の使用
AUPO727097A0 (en) 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
US6359152B2 (en) * 1997-07-21 2002-03-19 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
AUPP332898A0 (en) 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
AU758792B2 (en) * 1998-10-23 2003-03-27 Teijin Limited Vitamin D3 derivatives and remedies for inflammatory respiratory diseases containing the same
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6524594B1 (en) * 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
US6555710B1 (en) * 1999-07-16 2003-04-29 Leo Pharmaceutical Products Ltd A/S Lovens Kemiske Fabrik Produktionsaktieselskab Aminobenzophenones as inhibitors of IL-1 β and TNF-α
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
FR2798855B1 (fr) * 1999-09-28 2003-04-25 Oreal Utilisation de complexes inorganiques-organiques dans une composition a usage topique
US6703380B2 (en) * 1999-09-29 2004-03-09 Colotech A/S Prevention of cancer
WO2001025226A1 (en) * 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
ATE362912T1 (de) * 1999-12-06 2007-06-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
TR200401217T4 (tr) * 2000-03-07 2004-06-21 Aventis Pharma Deutschland Gmbh İkameli 3-Fenil-5-Alkoksi-1,3,4-Oksdiazol-2-one (ve) hormona duyarlı lipazın önlenmesinde kullanılması
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
IL153395A0 (en) * 2000-06-15 2003-07-06 Chugai Pharmaceutical Co Ltd Vitamin d derivatives
AU7895601A (en) * 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
ES2283593T3 (es) * 2001-10-12 2007-11-01 Johns Hopkins University Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.

Also Published As

Publication number Publication date
DE69824622D1 (de) 2004-07-22
EP1491198A1 (de) 2004-12-29
ES2222615T3 (es) 2005-02-01
JP2001517705A (ja) 2001-10-09
EP1030670A1 (de) 2000-08-30
US6087350A (en) 2000-07-11
US20030176403A1 (en) 2003-09-18
WO1999016451A1 (en) 1999-04-08
US20030216359A1 (en) 2003-11-20
US6559139B1 (en) 2003-05-06
PT1030670E (pt) 2004-09-30
AU1359499A (en) 1999-04-23
EP1030670B1 (de) 2004-06-16
US20080003304A1 (en) 2008-01-03
DK1030670T3 (da) 2004-10-04
DE69824622T2 (de) 2009-09-24

Similar Documents

Publication Publication Date Title
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
DK1035834T3 (da) Osmotisk doseringsform omfattende en første og anden coating
DE69812949D1 (de) Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
PL334348A1 (en) Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
TW234691B (de)
DK1206261T3 (da) Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
DE69710065D1 (de) Androsten-derivate
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
DE60044674D1 (de) Verwendung von rhamnolipiden zur wundheilung, behaund periodontaler regeneration
MX9307509A (es) Metodo y preparacion farmaceutica para reducir la actividad de las celulas.
DK0539479T3 (da) Heterocykliske forbindelser
AR012853A1 (es) Formulacion inyectable transparente de compuesto anestesico
ATE173627T1 (de) Medizinische zusammensetzung
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
TR199900013T2 (xx) Yeni bile�ikler.
ES2138668T3 (es) Nuevos derivados de peptidos terapeuticamente activos en la cadena de coagulacion sanguinea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.
FR2567755B1 (fr) Nouveau medicament anti-tumoral contenant comme ingredient actif le triacetoxy-1,8,9 anthracene
AR003117A1 (es) El uso de derivado de aminotetralina para la preparacion de composiciones farmaceuticas para la terapia de enfermedades cardiovasculares y dichascomposiciones farmaceuticas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1030670

Country of ref document: EP